Proximal Femoral Nail Antirotation (PFNA) Versus PFNA Augmentation

Exclusion Criteria

• •Pathologic fracture
• •Polytrauma
• •Any additional fracture
• •Open fracture
• •Recent history of substance abuse (ie, recreational drugs, alcohol) that would preclude reliable assessment
• •Active malignancy defined as history of invasive malignancy, except if the patient has received treatment and displayed no clinical signs and symptoms for at least five years
• •ASA class V and VI
• •Any implant at the same hip
• •Hemiplegia
• •Patients with legal guardian
• •Patients who have participated in any other device or drug related clinical trial that could influence the results of the present study within the previous month
• •Fractures and injuries opening into the articulation and vascular structure
• •Infection
• •Patients with clotting disorders
• •Patients with severe cardiac and / or pulmonary insufficiency
• •Patients with known hypersensitivity or allergy to any of the components of Traumacem V+ cement (Polymethyl methacrylate / acrylate, zirconium dioxide, hydroxyapatite,benzoyl peroxide, methyl methacrylate,hydroquinone, N,N-dimethyl-p-toluidine)
• •Perforation of the femoral head into the joint with the guide wire used for the PFNA blade
• •Risk of potential leakage into the joint identified by using contrast fluid (PFNA Augmentation group only)
• •Intraoperative decision to use implants other than PFNA